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Abstract
Amplification of the MYCN proto-oncogene is associated with a poor prognosis in patients with metastatic neuro-
blastoma (NB). MYCN encodes the N-Myc protein, a transcriptional regulator that dimerizes with the Max trans-
cription factor, binds to E-box DNA sequences, and regulates genes involved in cell growth and apoptosis.
Overexpression of N-Myc leads to transcriptional activation and an increase in NB cell proliferation. Mxi1, a mem-
ber of the Myc family of transcriptional regulators, also binds to Max. However, Mxi1 is a transcriptional repressor
and inhibits proliferation of NB cells, suggesting that Mxi1 functions as an N-Myc antagonist. Our laboratory pre-
viously identified Mxi1-0, an alternatively transcribed Mxi1 isoform. Mxi1-0 has properties distinct from those of
Mxi1; in contrast to Mxi1, Mxi1-0 is unable to suppress c-Myc–dependent transcription. We now show that Mxi1-0
expression increases in response to MYCN overexpression in NB cells, with a positive correlation between MYCN
and MXI1-0 RNA levels. We also show that N-Myc expression differentially regulates the MXI1 and MXI1-0 promo-
ters: Increased MYCN expression suppresses MXI1 promoter activity while enhancing transcription through the
MXI1-0 promoter. Finally, induction of Mxi1-0 leads to increased proliferation, whereas expression of Mxi1 inhibits
cell growth, indicating differential roles for these two proteins. These data suggest that N-Myc differentially
regulates the expression of MXI1 and MXI1-0 and can alter the balance between the two transcription factors.
Furthermore, MXI1-0 appears to be a downstream target of MYCN-dependent signaling pathways and may
contribute to N-Myc–dependent cell growth and proliferation.
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Introduction
Neuroblastoma (NB) accounts for 8% to 10% of all childhood cancers
[1,2]. Amplification of the MYCN proto-oncogene is associated with
disease progression in patients with advanced stage NB, and MYCN
amplification is currently used in risk stratification protocols as a neg-
ative prognostic indicator [3–6]. Ectopic expression of MYCN in cells
results in neoplastic transformation [7,8], and targeted expression of
MYCN to the neuroectoderm of transgenic mice results in spontaneous
development of NB tumors [9]. While MYCN amplification clearly
serves as a marker for high-risk NB, the precise mechanisms by which
MYCN contributes to the pathogenesis of NB remain poorly under-
stood. Identification of a means to overcome the effects of MYCN
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amplification could dramatically affect the outcome of patients with
high-risk NB.
The modulation of Mxi1 activity represents a potential mechanism
for interfering with N-Myc activity. The MXI1 gene, also known as
Max Interactor 1, is a member of the MAD gene family [10–12] and
encodes the Mxi1 protein [13]. Mxi1 acts as a transcriptional repressor
causing histone deacetylase–dependent chromatin condensation [14–
18]. Additionally, Mxi1 competes with Myc for binding sites in the
regulatory regions of Myc-dependent genes, repressing transcription,
thus functioning as a Myc antagonist [13,19].Mxi1 has attracted recent
attention, as it has been shown to be involved in a hypoxia pathway
regulated by hypoxia inducible factor-1 alpha (HIF1α) and may play
a role in von Hippel–Lindau–deficient tumorigenesis [20–23]. More-
over, Mxi1 has recently been described as a target of microRNAs in
erythroid development [24] and gliomas [25]. Because Mxi1 has pre-
viously been shown to mediate transcriptional repression of theMYCC
gene itself and suppresses c-Myc–dependent neoplastic transformation
[26,27], we hypothesize that Mxi1 may modulate N-Myc function in
a similar fashion in human NB.
Our laboratory identified the alternatively transcribed Mxi1 iso-
form, Mxi1-0 [28]. TheMXI1-0 transcript is identical toMXI1, except
that it has an alternative first exon (Exon 0) that lies upstream of
the first MXI1 exon (Exon 1) [21]. This exon encodes 61 additional
N-terminal amino acids without homology to any known motifs.
MXI1-0 andMXI1 are co-expressed at varying levels in different human
and murine tissues [28]. In contrast to MXI1, MXI1-0 mRNA is
expressed more prominently in human fetal tissue than in adult tissues
[28]. Our studies show that overexpression of Mxi1-0 has no effect on
the proliferation of c-MYC–transfected Rat1a fibroblasts, unlike Mxi1,
which strongly suppresses growth of MYC-amplified cells [28]. This
raises the intriguing possibility that the same gene gives rise to two
transcripts with distinct functions. The identification of MXI1-0 pro-
vides an additional mechanism by which the members of the Myc
family may interact with one another. In examining the relationship
between expression ofMYCN andMXI1/MXI1-0 in NB cells, we show
thatN-Myc differentially regulates the expression ofMXI1 andMXI1-0.
Thus, differential regulation may provide NB with a proliferation
advantage. These observations highlight the complexity of regulation
by the Myc family of transcriptional regulators.
Materials and Methods
Plasmid Construction
The pCMV MYCN plasmid was a gift (William Fahl, Madison,
WI). The pEFGP β-actin plasmid was purchased from Clontech
Laboratories (Mountain View, CA). MXI1 andMXI1-0 cDNAs were
amplified from a human heart cDNA library (BD Biosciences/Clontech,
Palo Alto, CA) using BamH1 sequence containing forward primers
(5′-CGGGATCCCATGGGCAAACGCGGGCGG-3′ and 5′-CGCG-
GATCCTCTAGACCATGGAGCGGGTGAAGATGATC-3′,
respectively), and a reverse primer (5′-CGCGGATCCTTAAGCG-
TAGTCTGGGACGTCGTATGGGTACAAGCTTGAAGTGAAT-
GAAAGTTTGAC-3′). MXI1 and MXI1-0 cDNAs were subcloned
into the pcDNA3.1 eukaryotic expression vector (Invitrogen, Carlsbad,
CA). The p3B/MXI1 and p3B/MXI1-0 promoter constructs were
made by cloning the 1-kb fragment of genomic sequence preceding
the MXI1 or MXI1-0 ATG upstream of the promoterless luciferase
gene in the XhoI/NcoI sites of the pGL3-Basic vector (Promega,
Madison, WI). The pLVX-MXI1-FLAG and pLVX–MXI1-0–FLAG
constructs were created by subcloning the MXI1 or MXI1-0 cDNA
sequences from the p3X-FLAG expression vector into the pLVX-
Tight-Puro lentiviral vector (Clontech Laboratories) at the NotI site.
The FLAG sequence was then cloned downstream into the vectors at
the EcoRI site. DNA sequencing using the fluorescent dideoxy termi-
nator method of cycle sequencing on a PE/ABd 373a automated DNA
sequencer following ABd protocols at the University of Michigan DNA
Sequencing Core was performed to confirm appropriate sequence and
orientation of each plasmid vector.
Cell Culture
SHEP, SHEP/MYCN, SH-IN, SH-SY5Y, SK-N-AS, SK-N-BE,
SK-N-SH, KCNR, IMR32, and GOTO human NB cell lines (gifts
of Valerie Castle, Ann Arbor, MI) were maintained in RPMI-1640
supplemented with 10% FBS and 50 μg/ml penicillin/streptomycin
(Invitrogen/Gibco BRL, Rockville, MD) at 37°C in a humidified
atmosphere with 5% CO2. MYCN3-inducible cell line (gift of Jason
Shohet, Houston, TX) was maintained in Dulbecco’s modified
Eagle’s medium supplemented with 10% tetracycline-free FBS and
50 μg/ml penicillin/streptomycin (Invitrogen/Gibco BRL) at 37°C
in a humidified atmosphere with 5% CO2. Cells were plated into
100 mm × 20 mm tissue culture dishes (Corning, Corning, NY)
and passaged with 0.25% trypsin-EDTA (Invitrogen/Gibco BRL).
Mxi1 or Mxi1-0–inducible cells were created by stably inserting
the MXI1 or MXI1-0 genes into IMR-32 cells with the Lenti-X
Tet-On Advanced Inducible Expression System (Clontech Labora-
tories) lentivirus according to the manufacturer’s instructions. Single
cell colonies were isolated and screened for sufficient Mxi1 or Mxi1-0
induction. Multiple clones were used in the experiments. Cells were
maintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% tetracycline-free FBS and 50 μg/ml penicillin/streptomycin
(Invitrogen/Gibco BRL) at 37°C in a humidified atmosphere with 5%
CO2. Induction of expression was effected by exposure to 750 ng/ml
doxycycline for 48 hours.
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
Total RNA was extracted from NB cell lines with TRIzol reagent
(Invitrogen/Gibco BRL) according to the manufacturer’s instruc-
tions. For standard reverse transcription–polymerase chain reaction
(RT-PCR), 1 μg of total RNA was reverse transcribed using the
Superscriptase II kit (Invitrogen/Gibco BRL) using oligo dT as
a primer to select for mRNA. PCR on the cDNA was done on an
iCycler thermocycler (Bio-Rad, Hercules, CA) using Taq polymerase
(Invitrogen/Gibco BRL) according to the manufacturer’s instruc-
tions. The reaction conditions were 95°C for 4 minutes and 30 cycles
of 95°C for 30 seconds, 61°C for 45 seconds, and 72°C for 45 sec-
onds. Real-time RT-PCR was performed on an iCycler iQ Real-
Time Detection System with an iScript One-Step RT-PCR Kit with
SYBR Green (Bio-Rad) according to the manufacturer’s instructions.
The amount of total RNA used was 10 ng. The reaction conditions
were 50°C for 25 minutes, 95°C for 10 minutes, and 45 cycles of
95°C for 30 seconds, 61°C for 45 seconds, and 69°C for 45 seconds.
The following primer sets were used for both standard and real-time
PCR reactions: MXI1-0 forward primer (5′-GACATTTTCAA-
CACCAGCGAGAACTCGATG-3′), MXI1 forward primer (5′-
CAACGTGCAGCGTCTGCTGGAGGC-3′), MXI1-0 and MXI1
1364 N-Myc Differentially Regulates MXI Isoforms Armstrong et al. Neoplasia Vol. 15, No. 12, 2013
reverse primer (5′-CGATTCTTTTCCAGCTCATTGTG-3′),MYCN
forward primer (5′-AGGACACCCTGAGCGATTCAG-3′), MYCN
reverse primer (5′-GGAGAGGGGGCGGCATAGGCA-3′), β-actin
forward primer (5′-TCACCCACACTGTGCCCATCTACGA-3′),
and β-actin reverse primer (5′-CAGCGGAACCGCTCATTGC-
CAATGG-3′). A melt curve profile was generated after every run to
verify primer specificity for each reaction. To determine copy number,
real-time PCR was also run on the plasmids pcDNA3.1/MXI1-0,
pcDNA3.1/MXI1, pCMV/MYCN, and pEFGP/β-actin at the follow-
ing concentrations: 100 fg, 1 pg, 10, pg, 100 pg, 1 ng, and 10 ng of
plasmids. These amounts were converted to copy number by the follow-
ing equations from Applied Biosystems (Foster City, CA): Mass of one
plasmid = (plasmid size in base pairs) * (1.096 × 10−21 g per base pair);
copy number = (mass of total plasmid used) ÷ (mass of one plasmid).
For each real-time RT-PCR run, a threshold relative fluorescence
unit value was chosen on the basis of approximately 50% total PCR
product made. The cycle at which this threshold was crossed was
plotted against copy number of plasmid added to the reaction mix.
From this, a standard curve of cycle number to copy number was
generated for each plasmid. The cycle number determined for each
total RNA sample from the cells was compared to the appropriate
standard curve and a copy number calculated from the equation of
a line (y = mx + b). The slope and y-intercept were calculated from
the linear regression of each standard curve.
Transfection and Luciferase Assays
SHEP cells were plated into 12-well plates (Corning) at 1 × 105 cells
per well. After 24 hours, cells were transiently transfected with 1 μg
of either p3B/MXI1 or p3B/MXI1-0 promoter plasmid with 10 ng of
Renilla luciferase plasmid (pRL-TK) and 0, 1, 2.5, or 5 μg of a pCMV
MYCN expression vector (empty pCMV vector was used to equalize
the total amount of DNA, transfected to 5 μg) using FuGENE 6
(Roche Diagnostics, Indianapolis, IN). Briefly, 3 μl of FuGENE 6
and 1 μg of plasmid DNA were added to 0.2 ml of Opti-MEM
(Invitrogen/Gibco BRL) for 15 minutes. This mixture was then added
dropwise to cells in Opti-MEM media. After 4 hours, culture media
Figure 1. N-Myc alters the balance ofMXI1-0 andMXI1mRNA expression.MXI1-0 andMXI1 expression in SHEP and SHEP/MYCN cells.
Real-time RT-PCR was performed on RNA from SHEP and SHEP/MYCN cells using primers specific for MXI1-0 and MXI1. (A) An
amplification plot was generated each for cell type and amplified transcript. The cycle number at threshold fluorescence was also
determined. (B) Real-time PCRwas also run on various concentrations of pcDNA3.1/MXI1-0 or pcDNA3.1/MXI1 to generate cycle number
to copy number standard curves. The cycle numbers generated from the SHEP and SHEP/MYCN RNA were plotted on the standard
curves to extrapolate copy numbers. Extrapolated copy numbers were plotted and compared. *P < .05 compared to SHEPMXI1. #P < .05
compared to SHEP MXI1-0.
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containing 10% FBS were added back to the cells. In experiments using
the inducible MYCN3 cell line, 4 μg/ml doxycycline was added along
with the culture media. The cells were harvested after 48 hours, and
both luciferase and Renilla activities were measured on a Monolight
3010 Luminometer (BD Pharmingen, San Diego, CA) using the
Dual-Luciferase Assay System (Promega). Luciferase activity values were
normalized to the Renilla activity for each sample (L/R).
Cell Proliferation Assay
Mxi1-0 and Mxi1-inducible IMR-32 cells were plated into 96-well
plates at 5000 cells per well. MXI1 and MXI1-0 gene expression was
induced by treatment with 750 ng/ml doxycycline for 48 hours. After
gene induction, cell proliferation was measured with the Cell Pro-
liferation ELISA, BrdU (Roche Diagnostics) according to the manu-
facturer’s instructions. In brief, cells were exposed to bromodeoxyuridine
(BrdU) for 2 hours, washed, fixed, and then incubated with anti-BrdU
antibody for 90minutes. Antibody binding was detected colorimetrically
on a plate reader at 370 nm. Data are expressed as percent of untreated
control cells after subtraction of background.
Statistical Analyses
Linear regression was used to determine degree of correlation. The
two-tailed Student’s t test was used to compare two groups. Signifi-
cance was considered to be P < .05. Data are reported as the mean ±
standard error unless otherwise stated. All assays were done in tripli-
cate and repeated at least three times.
Results
MXI1-0 mRNA Expression Is Increased in a
MYCN-Overexpressing NB Cell Line
To determine the effect of N-Myc expression on the relative levels
of MXI1 and MXI1-0 in NB cells, we performed quantitative real-
time RT-PCR using primers specific for MXI1 and MXI1-0 on RNA
prepared from SHEP cells and SHEP cells stably engineered to con-
stitutively expressMYCN (SHEP/MYCN). Dramatically higher levels
of MXI1-0 mRNA are detected in MYCN-overexpressing SHEP/
MYCN cells as compared with control SHEP cells (Figure 1A). Quan-
titation reveals that when MYCN is stably overexpressed in SHEP
cells, the expression ofMXI1-0 increases relative to untransfected cells
(Figure 1B). Specifically, the copy number of MXI1-0 increases more
than three-fold, from less than 250,000 to ∼750,000. These results
suggest that MYCN upregulates the expression of MXI1-0.
MYCN Amplification Is Associated with Relatively Increased
Expression of MXI1-0 mRNA
The above observations indicate that N-Myc upregulates MXI1-0
expression in NB cells. However, MYCN is not natively expressed in
SHEP cells, so the forced overexpression may not be physiologic. We
therefore examined the relative expression of MXI1 and MXI1-0 in
NB cell lines with different intrinsic levels of MYCN expression and
phenotypes of varying aggressiveness. We performed RT-PCR using
total RNA extracted from nine human NB cell lines. The SHEP,
SH-SY5Y, SH-IN, SK-N-SH, and SK-N-AS cell lines are MYCN
non-amplified cell lines. The SHEP/MYCN cell line was produced
by stable MYCN transfection into non-amplified SHEP cells and
has very high MYCN expression. The IMR-32, KCNR, GOTO,
and SK-N-BE cell lines are natively MYCN-amplified cell lines.
MYCN mRNA expression in each of these cell lines is shown in
Figure 2A. β-actin mRNA expression levels were similar between
the non-amplified and amplified cell lines (data not shown). To con-
firm the impact of MYCN expression on MXI1 and MXI1-0 mRNA
levels, we measured the relative expression of MXI1-0 and MXI1
Figure 2. N-Myc increasesMXI1-0/MXI1 expression ratios in native
MYCN-expressing NB cells. MYCN/β-actin and MXI1-0/MXI1 ratios
in NB cell lines. Real-time RT-PCR was used to determine the copy
number of MYCN, β-actin, MXI1-0, and MXI1 in a number of NB
cell lines. The ratios of MYCN to β-actin (A) and MXI1-0 to MXI1
(B) were calculated and plotted. These ratios were plotted against
each other (C), and linear regression was used to determine the
correlation between these ratios (r2 = 0.9359, P < .05).
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mRNA in MYCN-amplified versus non-amplified NB cell lines
(Figure 2B). The results demonstrate that in all five cell lines with
high MYCN expression, the ratio of MXI1-0/MXI1 expression is
always greater than 4 (range of 4.3-12.2), whereas the non-amplified
cell lines have a ratio of less than 1 (range of 0.60-0.94). Further-
more, the ratio ofMXI1-0/MXI1 increases from 0.63 to 4.3 in SHEP
(low MYCN) to SHEP/MYCN (high MYCN), respectively (Fig-
ure 2B). These results indicate that the ratio of MXI1-0/MXI1 is
highly correlated with native MYCN expression in NB cell lines,
where high MYCN expression is associated with a relative increase
in MXI1-0 expression. The relationship between MXI1-0 and
MXI1 expression with MYCN expression in each of the cell lines
was determined by linear regression; Figure 2C demonstrates a linear
relationship between relative MXI1-0/MXI1 levels and MYCN
expression. We also performed similar RT-PCR using primers specific
to other MAD family members including MAD-1, MAD-3, and
ROX/MNT. There was no difference in expression of MAD-1,
MAD-3, or ROX/MNT RNA in amplified versus non-amplified cell
lines (data not shown), suggesting that the effect of MYCN on the
expression of MAD family members is specific to the MXI1 locus.
Increased MYCN Expression Leads to Increased MXI1-0
Promoter Activity
Because there appears to be a clear correlation between MYCN
expression and higher MXI1-0 mRNA levels, we next sought to
determine whether this effect is due to alterations in MXI1-0/MXI1
promoter activity. N-Myc could potentially directly regulate transcrip-
tion through the MXI1 and MXI1-0 promoters, leading to a change
in relative expression of the two transcription factors. We transiently
transfected SHEP NB cells with increasing amounts of MYCN expres-
sion plasmid (pCMV–N-MYC) and eitherMXI1 orMXI1-0 promoter
luciferase reporter plasmids. As shown in Figure 3A,MXI1-0 promoter
activity increased by approximately 250% in response to increasing
levels of MYCN from 0 to 5 μg. Conversely, MXI1 promoter activity
decreased by 30% in response to increasing levels ofMYCN expression
(Figure 3B). These results indicate that N-Myc shifts the balance of
Mxi1-0 and Mxi1 in NB cells by upregulating MXI1-0 expression
while simultaneously downregulating MXI1.
N-Myc Modulates Expression of MXI1 through Initiator
Promoter Elements
Because MXI1 promoter activity decreased with increasing titra-
tion ofMYCN (Figure 3B), we explored possible mechanisms for this
effect. Myc is known to repress some target genes through Initiator
(Inr) elements [29,30]. To investigate whether N-Myc represses
MXI1 promoter expression through these elements, we constructed a
mutant MXI1 promoter lacking all six putative Inr elements. N-Myc–
inducible MYCN3 cells were transiently transfected with intact MXI1
promoter (p3B1084) or an Inr-deleted promoter (p3B1/2/3 Del).
N-Myc expression was induced by the addition of doxycycline. Pro-
moter activity was measured and normalized to constitutive Renilla
activity. As shown in Figure 4, deletion of Inr elements significantly
decreased the repression of MXI1 promoter activity in the presence
of high levels of N-Myc. This suggests that N-Myc represses MXI1
promoter activity through Inr elements, and when that mechanism
Figure 3. N-Myc altersMXI1-0 andMXI1 promoter activities. SHEP
cells were transfected with an MXI1-0 or MXI1 luciferase reporter
plasmid (p3B/MXI1-0 and p3B/MXI1, respectively) and a Renilla
reniformis luciferase plasmid (pRL-TK, internal control). Varying
amounts of a MYCN expression plasmid (pCMV MYCN) were also
transfected into these cells. After 48 hours, the mean luciferase
activity (luciferase/Renilla) was determined. *P < .05 when com-
pared to no MYCN.
Figure 4. N-Myc exerts its inhibitory effects through Inr elements.
Inducible MYCN cells, MYCN3, were transiently transfected with a
luciferase plasmid containing the wild-typeMXI1 promoter (Exon 1)
or anMXI1 promoter with deletion of all Inr elements (Del Exon 1).
After transfection, N-Myc expression was induced by adding doxy-
cycline. Cells were incubated for 36 hours. The relative promoter
activity for both vectors is shown in the absence and presence of
N-Myc. *P < .01, **P = .01.
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of inhibition is removed, the MXI1 promoter retains high activity
even in the presence of high levels of N-Myc.
MXI1-0 Stimulates while MXI1 Inhibits NB
Cell Proliferation
The differential regulation of MXI1 and MXI1-0 by N-Myc sug-
gests the possibility of contrasting effects on NB proliferation. To
examine the impact of Mxi1 and Mxi1-0 on N-Myc–mediated NB
cell proliferation, MXI1 and MXI1-0–inducible cell lines were grown
in the presence or absence of the inducing agent, doxycycline, and
cell proliferation was measured with a BrdU assay. Induction of each
respective gene was verified by quantitative PCR (Figure 5A). As can
be seen in Figure 5B, induction of Mxi1 expression leads to signifi-
cantly decreased NB cell proliferation relative to uninduced control
cells. In contrast, increased expression of Mxi1-0 promotes NB cell
proliferation (Figure 5B). This differential response indicates oppos-
ing roles of Mxi1 and Mxi1-0 in NB cell proliferation. These data
suggest that by shifting the MXI1-0/MXI1 balance toward MXI1-0,
N-Myc may facilitate NB cell proliferation.
Discussion
The MYCN oncogene is amplified in 40% of patients with advanced
stage NB and portends a poor prognosis [3,31,32]. Although MYCN
is a well-defined marker for advanced NB [6], the precise mecha-
nisms by which MYCN amplification and deregulated N-Myc
protein expression contribute to the pathogenesis of NB remain
poorly understood. By acting as a transcriptional regulator of
growth-related target genes, N-Myc plays a critical role in cell prolif-
eration and differentiation, control of the cell cycle, and apoptosis
[33–35]. Ectopic expression of MYCN in cells leads to neoplastic
transformation [7,8], and targeted expression of MYCN to the neuro-
ectoderm of transgenic mice results in NB-like tumors [9]. Conversely,
antisense MYCN expression and MYCN siRNA knockdown result in
reduced cellular proliferation [36]. These observations suggest that
antagonism of N-Myc expression interferes with the aggressiveness
of MYCN-amplified NB. There are currently no known agents that
effectively target N-Myc or its downstream mediators to diminish the
malignant capacity ofNB.Here, we describe interactions amongN-Myc,
its naturally occurring antagonist Mxi1, and Mxi1-0, a novel Mxi1 iso-
form, and suggest mechanisms that could potentially be exploited to
diminish N-Myc activity in NB.
Mxi1 plays an important role in regulating cell growth and prolif-
eration at least in part by antagonizing Myc family members [26,27].
Loss of Mxi1 function has been implicated in the pathogenesis of
several malignancies. In glioblastoma tumors that exhibit loss of hetero-
zygosity at the MXI1 locus on chromosome 10 [27], MXI1 haplo-
insufficiency may provide a growth advantage as a result of loss of
repression of c-Myc. Furthermore, exogenous expression of Mxi1 in
glioblastoma cell lines leads to decreased proliferation and increased
rates of apoptosis [27]. Intriguingly, regulation of MXI1 by micro-
RNAs has recently been reported to play a role in glioma cell pro-
liferation [25]. MXI1 mutations have also been identified in prostate
cancer cells and neurofibromas [37], and overexpression of Mxi1 in
prostate cancer cell lines results in decreased cell proliferation [38].
Conversely, targeted knockout of the mxi1 gene in mice leads to the
development of B-cell lymphomas, and tumor promotion by 7,12-
dimethylbenz(a)anthracene (DMBA) application results in accelerated
lymphoma and skin cancer formation in these mice [37,39], suggesting
that the absence of mxi1 potentiates tumorigenesis. Mxi1 expression is
also induced in response to cellular stress such as exposure to hypoxic
conditions [20,21]. Finally, altered MXI1 expression has been asso-
ciated with perturbations in kidney development, in the context of
polycystic kidney disease [40,41] and epithelial tubulogenesis [42].
Taken together, these findings indicate that Mxi1 plays a critical role
in controlling cell proliferation and suppressing malignant potential.
Since the initial identification of the MXI1 gene in 1993 [13],
several Mxi1 protein isoforms have been described. While screening
for genes that are upregulated in human NB cells, our laboratory
described Mxi1-0 as a novel Mxi1 isoform [28]. Mxi1-0 has a dis-
tinct 60 amino acid N-terminal (encoded by an alternative first exon)
that includes domains without homology to known protein motifs.
Unlike Mxi1, which exhibits a predominantly nuclear localization
pattern, Mxi1-0 primarily localizes to the cytoplasm (unpublished
observations). In contrast to Mxi1, Mxi1-0 is unable to inhibit
Figure 5. Mxi1-0 promotes while Mxi1 expression inhibits NB cell
proliferation. (A) Expression of inducedMXI1 andMXI1-0 is shown
with β-actin as loading control (expressed as fold over the non-
induced state). *P < .01 versus non-induced controls. (B) MXI1
and MXI1-0–inducible IMR-32 cells were plated into 96-well
plates, and expression was induced by exposure to doxycycline
for 48 hours. Cell proliferation was assessed by BrdU assay and is
shown as percent viability compared with untreated control cells.
Dashed line indicates 100% viability of control cells and demon-
strates reduced viability with MXI1 and increased viability with
MXI1-0. *P < .01 versus MXI1.
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Myc-dependent transcription [28]. Similar isoforms have been
described in mice: mxi1-SRβ and mxi1-SRα are homologous to
human MXI1 and MXI1-0, respectively [43]. Like Mxi1 and Mxi1-0,
both mxi1-SRβ and mxi1-SRα have Sin3 interaction domains [43].
Additionally, bothMxi1 andmxi1-SRβ inhibit the transcriptional activ-
ity of Myc; however, the inhibitory functions of mxi1-SRα remain
unclear [43–45].
In this report, we show that human MXI1 and MXI1-0 are differ-
entially regulated by N-Myc in NB cell lines. Specifically, we dem-
onstrate that N-Myc represses transcription ofMXI1 and is associated
with relatively increased expression ofMXI1-0 (Figures 2 and 3). The
association of N-Myc expression with relatively increased Mxi1-0
levels, at the expense of Mxi1, suggests a mechanism whereby N-Myc
may potentiate its own activity by reducing expression of its antagonist
Mxi1. We hypothesize that co-expression of Mxi1-0 with Mxi1 mod-
ulates the suppressive activity of Mxi1 and that relative overexpression
of Mxi1-0 may contribute to increased proliferation in neoplastic
cells. This hypothesis is supported by NB cell proliferation data dem-
onstrating increased proliferation in the presence of Mxi1-0 and
impaired cell proliferation with expression of Mxi1 (Figure 5). It is
possible that Mxi1-0 disrupts Mxi1 activity in a dominant negative
fashion through sequestration of critical cofactors away from Mxi1,
interfering with its ability to suppress cell proliferation.
As noted, mature human tissues express a predominance of MXI1,
whereas in fetal tissues, the ratio shifts toward the expression of
MXI1-0 [28]. This shift in the Mxi1-0/Mxi1 balance has also been
described in other malignancies. Primary glioblastoma tumors display
a relatively increased MXI1-0/MXI1 ratio compared with normal
brain tissue [28]. In Barrett’s esophageal metaplasia, there is an up-
regulation of both MYCC and MXI1 [46]. However, in adenocarci-
noma of the esophagus, overexpression of MYCC leads to an increase
inMXI1-0 expression with no change inMXI1, and thus an increased
MXI1-0/MXI1 ratio [46]. The ability of MYCN to alter the MXI1-0/
MXI1 balance may be a mechanism by which N-Myc overexpression
potentiates its effects on increased proliferation, resulting in a more
aggressive phenotype.
Our results demonstrate a shift in the MXI1-0/MXI1 ratio in
MYCN-expressing NB cells. Expression of N-Myc results in a shift
in promoter activity with relatively reduced MXI1 and relatively
increased MXI1-0 expression, consistent with the effect seen in other
tissues as noted above. Furthermore, we demonstrate that N-Myc
represses MXI1 expression through Inr elements within the MXI1
promoter (Figure 4). Myc proteins have previously been shown to
repress other tumor suppressor genes through Inr elements. For
example, expression of cell cycle arrest genes such as GAS1, p15, p21,
p27, and GAD34 as well as adhesion molecules (N-cadherin and integ-
rins) is repressed by Myc [47,48]. Quantitation ofMXI1mRNA levels
(Figure 1) did not demonstrate a difference in transcript levels, even
though promoter activity is decreased in the presence of N-Myc (Fig-
ure 3). This discrepancy may be related to adaptation over time to ele-
vated N-Myc levels that are present in SHEP/MYCN cells, as compared
with the transient expression ofN-Myc in SHEP cells. In SHEP/MYCN
cells that display chronically elevated levels of N-Myc, there may be a
modification of MXI1 expression. However, despite this adjustment,
the overall ratio ofMXI1-0 toMXI1 still leans heavily toward the expres-
sion of MXI1-0. Furthermore, overexpression of Mxi1 and Mxi0 in
native MYCN-expressing IMR-32 NB cell lines demonstrated a differ-
ential role for each of these proteins inNB cell viability (Figure 5). These
observations suggest that Myc promotes malignancy through increased
cell proliferation and also by reducing expression of critical tumor sup-
pressor genes. This supports the hypothesis that N-Myc increases the
MXI1-0/MXI1 ratio as a way to block antagonism of its proliferative
effects. Potentially, shifting the balance back in favor ofMXI1maymake
NB more susceptible to current therapies.
In summary, our results define a role for N-Myc in the regulation
of MXI1 and MXI1-0 expression and suggest that N-Myc can mod-
ulate the expression of its own antagonist in NB cells. Induction of
MXI1-0 expression is one potential mechanism by which MYCN
potentiates the growth and proliferation of NB cells. Further under-
standing of the differential regulation of MXI1 and MXI1-0, as well
as identification of potential downstream mediators of Mxi1-0 activ-
ity, may allow for the development of targeted therapies that disrupt
the uncontrolled proliferation associated with MYCN amplification.
Our observations suggest a novel mechanism by which N-Myc activity
may be modulated, breaking the vicious N-Myc proliferation cycle.
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